A closely-watched Phase III study combining Merck’s PD-1 star Keytruda with Incyte’s IDO1 drug epacadostat for metastatic melanoma has failed, casting a pall over the future of this combination approach. Absent a significant improvement in progression-free survival, as well as the likely failure of the drug combination to extend overall survival, the investigators are halting … Continue reading Keytruda/epacadostat combo crashes in PhIII melanoma study, raising questions about the future of IDO for Incyte